Related Experiment Video

Updated: Feb 16, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.6K

Value in Using CAR T Cells for DLBCL

    Cancer Discovery
    |December 17, 2017
    PubMed

    Abstract:

    The phase II JULIET trial suggests that the CD19-targeting CAR T-cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large B-cell lymphoma. Three months after the therapy, 32% of the patients showed complete responses and 6% showed partial responses. After 6 months, those rates were 30% and 7%.

    More Related Videos

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    22.1K
    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    16.0K

    Related Experiment Videos

    Last Updated: Feb 16, 2026

    A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
    12:16

    A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

    Published on: October 16, 2018

    15.6K
    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    22.1K
    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    16.0K

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    2.0K
    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.0K

    Articles linked to this work by shared authors, journal, and citation graph.

    AI Model Predicts Cancer Development, Diagnoses Tumors.

    Cancer discovery·2026

    In Regulatory First, Myeloma Drug Approved Based on MRD Negativity.

    Cancer discovery·2026

    Transmissible Cancer Discovered in Catfish.

    Cancer discovery·2026

    Follicular Lymphoma Transformation is Characterized by Cytokine-associated Remodeling of Stromal and Macrophage Compartments.

    Cancer discovery·2026

    Genomics of Subsequent Neoplasms in Childhood Cancer Survivors.

    Cancer discovery·2026

    A Counterintuitive Approach to Cancer Therapy.

    Cancer discovery·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us